- Home
- VRCA vs IMRX Comparison
VRCA vs IMRX Comparison
Compare VRCA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | IMRX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 366.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRCA | IMRX |
|---|---|---|
| Price | $8.21 | $6.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.00 | ★ $17.20 |
| AVG Volume (30 Days) | 205.9K | ★ 1.3M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $373.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $1.10 |
| 52 Week High | $9.82 | $10.08 |
Technical Indicators
Market Signals| Indicator | VRCA | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 52.58 |
| Support Level | $7.60 | $6.49 |
| Resistance Level | $9.02 | $6.98 |
| Average True Range (ATR) | 0.88 | 0.41 |
| MACD | -0.13 | 0.08 |
| Stochastic Oscillator | 60.91 | 72.88 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.